FINWIRES · TerminalLIVE
FINWIRES

Update: Market Chatter: Novo Nordisk Seeks Immediate Court Order Against Lilly's Weight-Loss Drug Ads

By

(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.)

Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday.

According to the report, Novo Nordisk said it filed the request after suing Lilly earlier this week, alleging false advertising and unfair competition related to marketing campaigns for Zepbound and Mounjaro.

Novo alleges Lilly's ads misrepresented how the companies' drugs compare. Lilly denied the allegations and said it will vigorously defend the lawsuit, Reuters added.

In a statement emailed to, John Kuckelman, Senior Vice President and Group General Counsel, Novo Nordisk, said: "Millions of Americans living with obesity and type 2 diabetes rely on these medicines. Misleading advertisements that selectively compare lower doses of Novo Nordisk's medicines against higher doses of Lilly's medicines, based on outdated studies, leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true."

A Lilly spokesperson commented: "Head-to-head clinical trials are the strongest evidence for comparing medicines. SURMOUNT-5 and SURPASS-2 are the only head-to-head, randomized clinical trials directly comparing tirzepatide and semaglutide - and Novo Nordisk wants to stop Lilly from sharing their results. Novo Nordisk has never tested its highest doses of semaglutide against Lilly's tirzepatide medicines in any clinical trial; instead, it is using a lawsuit to advance comparisons it has never put to the test. We stand behind the science and our advertising, and we will oppose this motion vigorously."

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $48.98, Change: $+0.80, Percent Change: +1.65%

Related Articles

Wire

Business First Bancshares Q2 Earnings, Revenue Rise; Shares Drop After Hours

Business First Bancshares (BFST) reported core Q2 earnings late Thursday of $0.71 per diluted share, up from $0.66 a year earlier.Analysts polled by FactSet expected $0.70.Revenue in the three months ended June 30, expressed as net interest income plus total other income, rose to $91.8 million from $81.5 million.Four analysts expected $91.3 million.The company's shares fell 3.3% in after-hours trading.

$BFST
Wire

RingCentral Q2 Adjusted Earnings, Revenue Rise; FY Guidance Increases

RingCentral (RNG) reported Q2 non-GAAP net income late Thursday of $1.22 per diluted share, up from $1.06 a year earlier.Analysts polled by FactSet expected $1.16.Revenue in the three months ended June 30 rose to $657 million from $620 million a year earlier.Analysts expected $650.5 million.RingCentral expects Q3 non-GAAP EPS of $1.25 to $1.30 on revenue of $664 million to $670 million.Analysts expect EPS of $1.25 on revenue of $663.2 million.The company raised full-year non-GAAP EPS guidance to the range of $4.96 to $5.10 on revenue of $2.635 billion to $2.646 billion. The previous forecast was EPS of $4.85 to $5.01 on revenue of $2.62 billion to $2.64 billion.Analysts expect EPS of $4.92 on revenue of $2.63 billion.RingCentral shares rose 1.2% in after-hours trading.

$RNG
Wire

Robert Half Q2 Net Income, Revenue Fall; Shares Drop After Hours

Robert Half (RHI) reported Q2 net income late Thursday of $0.26 per share, down from $0.41 a year earlier.Analysts polled by FactSet expected $0.26.Revenue in the three months ended June 30 fell to $1.34 billion from $1.37 billion a year earlier.Analysts expected $1.32 billion.The company's shares fell 5.3% in after-hours trading.

$RHI